A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv11
  2. Site contacts updated at 30 of 30 sitesv10
  3. Trial sites expanded: 25 → 30 locationsv9
  4. Study sites: 24 to 25v8
  5. Site contacts updated at 24 of 24 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites revised (24)v6
  2. Site details revised at 6 of 24 sitesv5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 29 to 24
    • Start date changed from estimate of Dec 2025 to Nov 24, 2025
    v3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
365 trials monitored
See 16 trials at risk
Obesity
3,898 trials monitored
See 160 trials at risk
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.
Trial Details
NCT Number NCT07247084
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity
Related terms Obesity, Overweight
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov